Enhancement of the cytotoxicity of cisplatin by the cholecystokinin antagonist MK-329 in a human pancreatic cancer cell line.
Cholecystokinin (CCK) is an important trophic hormone for the pancreas, and CCK receptors are present on pancreatic carcinoma cells. We sought to determine whether either CCK itself or an antagonist of CCK could modulate the sensitivity of the human pancreatic cell line MIA-PaCa2 to cisplatin (DDP). The IC50 for a 1-h exposure to DDP was 35.3 +/- 3.2(SD) microM. Exposure to CCK8 octapeptide at physiologic and supra-physiologic concentrations did not alter the sensitivity of MIA-PaCa2 cells to DDP. The CCK receptor antagonist MK-329 was directly cytotoxic to the MIA-PaCa2 cells on a constant exposure schedule with an IC50 of 9.5 +/- 1.4 (SD) microM. MK-329 enhanced the sensitivity of MIA-PaCa2 cells to DDP by a factor of 3.5, and the interaction between DDP and MK-329 was shown to be synergistic by median-effect analysis. At a level of 50% cell kill, the combination index was 0.58 +/- 0.10. The ability of MK-329 to sensitize cells to DDP was schedule-dependent and required prolonged exposure to the antagonist following a 1-h exposure to DDP. MK-329 had no effect on the uptake of a radiolabeled analog of cisplatin ([3H]-dichloro(ethylenediamine)platinum) and did not affect intracellular glutathione content. MK-329 had no effect on the cell-cycle-phase distribution of MIA-PaCa2 cells and did not alter the DDP-induced cell-cycle perturbations. The cytotoxic effect of MK-329 and its ability to interact synergistically with DDP could not be reversed by CCK. We conclude that MK-329 is directly cytotoxic to pancreatic carcinoma cells and can enhance their sensitivity to DDP by a mechanism not related to its ability to antagonize the CCK receptor.
Jamshidipour
R
R
Department of Surgery, University of California, San Diego, La Jolla 92093.
Pinho
E B
EB
Hom
D K
DK
Howell
S B
SB
D000970:Antineoplastic Agents / Q000378:metabolism; D001570:Benzodiazepinones / Q000494:pharmacology*; D002453:Cell Cycle; D002766:Cholecystokinin / Q000037:antagonists & inhibitors*; D002945:Cisplatin / Q000494:pharmacology*; D020109:Devazepide; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006801:Humans; D009944:Organoplatinum Compounds / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D013997:Time Factors; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D001570:Benzodiazepinones; D009944:Organoplatinum Compounds; C002892:platinum ethylenediamine dichloride; D002766:Cholecystokinin; D020109:Devazepide; D002945:Cisplatin